MID-VOLUME · FEMALE-LED
tizanidine Side Effects
tizanidine (also sold as Zanaflex) sits MID-VOLUME #223 of 524 by FAERS report count. Lead signal: FEMALE-LED - 75% of sex-coded reports are female (15,795 F / 5,288 M). Demographics and serious-outcome tables follow.
Data updated 2026-05-15
- 22,750
- FAERS reports
FDA Adverse Event Reporting System extract for tizanidine. Stamp set WATCHLIST · DEATH-HEAVY · HOSP-MID. How figures are compiled.
tizanidine reporting skew - 75% of sex-coded reports are female (15,795 F / 5,288 M). Volume band MID-VOLUME #223 of 524 by FAERS report count; caseload WATCHLIST.
Mid-book FAERS page for tizanidine (Zanaflex) (22,750 reports). Signature FEMALE-LED. Dominant age band on file: 45-64. Educational reference only.
Counts from the openFDA FAERS extract (2004–2025). Stamps WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
FATIGUE leads 1,693 of 22,750 reports
FEMALE-LED reporters · age peak 45-64
Female-led reporters (75% of sex-coded rows)
Age peak 45-64 (7,737 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death-mentioned subset is HEAVY here (1,739 reports, 7.6%). Top co-reported reactions in that subset - voluntary, not causal.
| Reaction | Reports |
|---|---|
| DEATH | 499 |
| COMPLETED SUICIDE | 485 |
| TOXICITY TO VARIOUS AGENTS | 274 |
| CARDIO-RESPIRATORY ARREST | 129 |
| CARDIAC ARREST | 108 |
| SUSPECTED SUICIDE | 106 |
| ACUTE KIDNEY INJURY | 100 |
| CHRONIC KIDNEY DISEASE | 98 |
| RENAL FAILURE | 76 |
| RESPIRATORY ARREST | 72 |
| END STAGE RENAL DISEASE | 56 |
| PNEUMONIA | 47 |
| FALL | 44 |
| OVERDOSE | 38 |
| SEPTIC SHOCK | 36 |
| HYPOTENSION | 34 |
| ASTHENIA | 30 |
| DYSPNOEA | 29 |
| URINARY TRACT INFECTION | 29 |
Reactions in Hospitalization Reports
Hospitalization mid-share (6,474, 28.5%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| FALL | 598 |
| PAIN | 484 |
| NAUSEA | 480 |
| PNEUMONIA | 452 |
| URINARY TRACT INFECTION | 428 |
| FATIGUE | 424 |
| DYSPNOEA | 348 |
| ACUTE KIDNEY INJURY | 338 |
| HEADACHE | 337 |
| VOMITING | 337 |
| ASTHENIA | 325 |
| DIARRHOEA | 323 |
| HYPOTENSION | 323 |
| DIZZINESS | 299 |
| SOMNOLENCE | 299 |
| ARTHRALGIA | 257 |
| MULTIPLE SCLEROSIS RELAPSE | 252 |
| CHRONIC KIDNEY DISEASE | 248 |
How to read tizanidine FAERS figures (WATCHLIST · DEATH-HEAVY · HOSP-MID)
FAERS holds 22,750 voluntary reports linked to tizanidine (Zanaflex), 2004-2025. Death is listed on 1,739 (7.6%). Hospitalization appears on 6,474 (28.5%). Top co-reported indication: Product Used For Unknown Indication.
Mid-volume extract - treat DEATH-HEAVY · HOSP-MID as signal-detection rates next to 75% of sex-coded reports are female (15,795 F / 5,288 M).
Read with tizanidine
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-HEAVY · HOSP-MID stamps.
ABS(total_reports) peer at 22,775 FAERS cases (Δ 25 heavier vs tizanidine); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 22,556 FAERS cases (Δ 194 lighter vs tizanidine); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 23,037 FAERS cases (Δ 287 heavier vs tizanidine); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 23,107 FAERS cases (Δ 357 heavier vs tizanidine); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-HEAVY · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 54.5 pp vs tizanidine's DEATH-HEAVY): CASELOAD · HOSP-MID.
tizanidine stamps DEATH-HEAVY · HOSP-MID; FAERS outcome shares are signal-detection rates, not incidence. Read them next to caseload WATCHLIST and the label guide.